How does Yervoy (ipilimumab) work against cancer?
Yervoy is an immune checkpoint inhibitor. It works by blocking CTLA-4, a “brake” on T cells. CTLA-4 normally helps keep T-cell activity in check; when Yervoy blocks CTLA-4, it helps T cells become more activated and more able to attack cancer cells.
What does CTLA-4 normally do?
CTLA-4 is a regulatory receptor on T cells. When it’s engaged, it dampens T-cell responses. By inhibiting CTLA-4, Yervoy shifts the immune system toward stronger T-cell activation.
When would you expect Yervoy’s effects to show up?
Checkpoint inhibitors often work differently from chemotherapy. Responses may take time because the drug needs to help the immune system ramp up against the tumor. Some patients can see benefit later rather than immediately.
How is Yervoy different from other checkpoint drugs like Keytruda or Opdivo?
Yervoy targets CTLA-4. By contrast, many other immune checkpoint therapies target PD-1 (or PD-L1), which is a different pathway that also regulates T cells. Because these brakes are separate, CTLA-4 and PD-1-targeted drugs can be combined to affect the immune system in complementary ways (when clinicians choose that strategy).
What side effects can happen because it boosts immune activity?
Since Yervoy increases T-cell activity, it can also cause immune-related side effects, including inflammation in organs such as the skin, intestines, liver, lungs, or endocrine glands. These risks are a known trade-off with immune checkpoint inhibitors.
Sources
No sources were provided in the prompt, so I didn’t cite any.